Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML

Peking University

Status: Enrolling

Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia

Treatments: Other: MFC for the determination of leukemia stem cell

Study type: Observational

Funder types: Other

Identifiers

NCT06452732

PekingUPH Chang Ying-Jun

Details and patient eligibility

About

Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.

Enrollment: 283 estimated patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnoses candidates with acute myeloid leukemia.
• Lower than or equal to 18 years-old;
• Subjects are able to provide written informed consent.

Exclusion criteria

• Subjects who cannot comply with the study;
• Subjects with severe cardiac disease (ejection fraction<50% ), liver disease (total bilirubin >34umol/L, ALT and AST>1.5×upper limit normal) or kidney disease (Serum creatinine>130umol/L).
• Subjects with severe infection.
• Subjects with other conditions that cannot receive chemotherapy or transplantation.

Trial design

283 participants in 1 patient group

MRD monitoring

Treatment:

Other: MFC for the determination of leukemia stem cell